Genmab — Februar 2018
-
Jeg er enig Mcjean.
-
I also competely agree… In august nobody wanted to sell, because everything was hunky dory and everything could only get better. A very small miss in quarterly earnings and some miscommunication started a ridiculous slide which created more fear and uncertainty and increased selling.
-
Well, now everything IS better, we have more approvals, more trials, more clinical proof, longer PFS, more pipeline, more cash and more certainty about potential sales. AND David did not screw up. Solid sales forecast with a credible explanation and a good excuse for the stall in US sales- which will be solved.
-
Vi er dumpet ned under meget lav omsætning her på det sidste. Stigningen i dag er sket under stor omsætning. Det er godt.
-
Tror I virkelig shorterne giver op så let? Genmab har guidet pænt, de skal stadigvæk bevise de kan nå i mål. Vi så med Pandora hvor langt AQR gik.
-
vi burde måske købe Bergenbio:-)
-
så har vi både små og stor molekyler
-
store
-
haha
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind